Larinject 500mg Injection
Larinject 500mg Injection Original price was: ₹1,914.00.Current price is: ₹1,650.00.
Back to products
Lenangio 5mg Capsule
Lenangio 5mg Capsule Original price was: ₹632.00.Current price is: ₹480.00.

Ledifos Tablet

Original price was: ₹25,000.00.Current price is: ₹5,500.00.

Prescription Required

Salt : Ledipasvir,sofosbuvir

Manufacturer : HETERO HEALTHCARE LTD

Packing : 28 Tablet(S) In A Bottle

Description

PRODUCT INTRODUCTION

Ledifos Tablet is a revolutionary medication used in the treatment of chronic hepatitis C infection. It is a combination drug containing Ledipasvir and Sofosbuvir, both of which are potent antiviral agents. Ledipasvir belongs to the class of direct-acting antiviral (DAA) drugs known as NS5A inhibitors, while Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor. Together, they work synergistically to combat the hepatitis C virus (HCV) by inhibiting the replication of the virus in the body.

USES of Ledifos Tablet

Ledifos Tablet is primarily prescribed for the treatment of chronic hepatitis C infection in adults. It is indicated for use in patients with genotype 1, 4, 5, or 6 HCV infection, which are among the most prevalent genotypes worldwide. This medication is highly effective in both treatment-naive patients and those who have previously failed interferon-based therapy or have liver transplantation.

BENEFITS OF Ledifos Tablet

The benefits of Ledifos Tablet are manifold:

  • High Efficacy: Ledifos Tablet has demonstrated high rates of sustained virologic response (SVR), indicating a successful eradication of the hepatitis C virus from the body. Clinical trials have shown SVR rates exceeding 95% across different patient populations, including those with advanced liver disease.
  • Convenience: Ledifos Tablet is taken orally once daily, making it convenient and easy to adhere to the treatment regimen. This eliminates the need for injections or frequent visits to healthcare facilities.
  • Improved Safety Profile: Compared to older interferon-based therapies, Ledifos Tablet has a much-improved safety profile with fewer side effects. It is generally well-tolerated by patients, including those with comorbid conditions such as HIV infection or liver cirrhosis.
  • Broader Treatment Options: Ledifos Tablet provides a valuable treatment option for patients with difficult-to-treat genotypes of hepatitis C virus, including genotype 1, which historically has been associated with lower response rates to therapy. This expands the range of patients who can benefit from antiviral treatment.

SIDE EFFECTS OF Ledifos Tablet

While Ledifos Tablet is generally well-tolerated, like all medications, it can cause side effects in some individuals. Common side effects may include:

  • Headache: Some patients may experience mild to moderate headaches during treatment with Ledifos Tablet. These headaches are usually transient and resolve on their own.
  • Fatigue: Fatigue or tiredness may occur in some patients, especially during the initial weeks of treatment. It is important for patients to get an adequate amount of rest and inform their healthcare provider if the fatigue becomes bothersome.
  • Nausea: Nausea is another common side effect of Ledifos Tablet. This may manifest as a feeling of queasiness or an urge to vomit. In most cases, it is mild and transient, but if it persists, patients should consult their healthcare provider.
  • Insomnia: Some patients may experience difficulty sleeping or insomnia while taking Ledifos Tablet. This side effect can usually be managed with proper sleep hygiene practices or by adjusting the timing of medication administration.
  • Rash: In rare cases, Ledifos Tablet may cause skin rash or itching. Patients should notify their healthcare provider if they develop any skin changes while taking this medication.

References

  1. Gilead Sciences Ltd., Electronic Medicines Compendium (EMC), [Revised on Jan 2021] [Accessed on 16 May 2023], https://www.medicines.org.uk/emc/files/pil.11849.pdf
  2. Sharon Safrin, Antiviral Agents, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 863-894.
  3. Q.M. Anstee, D.E.J. Jones, Liver, and biliary tract disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 921-988.

Disclaimer

Singhla Medicos’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Singhla Medicos. Our mission is to support, not replace, the doctor-patient relationship.

Reviews (0)
Shipping & Delivery